MARC 主機 00000nam a2200493 i 4500 
001    978-94-007-7675-3 
003    DE-He213 
005    20170531155808.0 
006    m     o  d         
007    cr nn 008maaau 
008    170531s2017    ne      s         0 eng d 
020    9789400776753|q(electronic bk.) 
020    9789400776746|q(paper) 
024 7  10.1007/978-94-007-7675-3|2doi 
040    GP|cGP|erda 
041 0  eng 
050  4 RC847 
082 04 616.362075|223 
245 00 Biomarkers in liver disease /|cedited by Vinood B. Patel, 
       Victor R. Preedy 
264  1 Dordrecht :|bSpringer Netherlands :|bImprint: Springer,
300    1 online resource (xxvii, 1013 pages) :|billustrations, 
       digital ;|c24 cm 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    text file|bPDF|2rda 
490 1  Biomarkers in disease: methods, discoveries and 
505 0  Liver biomarkers and their applications to nutritional 
       interventions in animal studies -- AST-to-platelet ratio 
       index (APRI) as marker in liver disease -- Inflammatory 
       biomarkers in ascites -- Biomarkers for hepatocellular 
       carcinoma in East Asia -- Liver disease and acylcarnitines
       as mechanistic biomarkers -- Type VI Collagen: Biological 
       Functions and its Neo-epitope as Hepatic Fibrosis 
       Biomarker -- Fibrinogen α-chain as a serum marker of liver
       disease -- Monocyte chemotactic protein-1 (cytokine, 
       receptors,and gene polymorphisms) in hepatitis -- 
       Biomarkers for Recurrence of Hepatocellular Carcinoma -- 
       Graft-derived cell-free DNA as a biomarker in liver 
       transplantation -- Serum sialic acid as a biomarker in 
       liver disease -- CD133 and EpCAM as Biomarkers in Liver 
       Diseases -- Traditional markers in liver disease -- 
       Biomarkers of extracellular matrix remodeling in liver 
       diseases -- Squamous Cell Carcinoma Antigen- 
       Immunoglobulin M (SCCA-IgM) as biomarker in liver disease:
       biological aspects and clinical applications -- microRNA-
       155 and microRNA-196b in hepatitis C virus infection -- 
       Immunological biomarkers in liver transplantation -- 
       Phosphatidylethanol and alcohol use in liver disease 
       patients -- Interaction of sialyltransferases, sialidases 
       and sialic acids in liver diseases and applications to 
       biomarker discovery -- Biomarkers to monitor graft 
       function following liver transplantation -- YKL-40 as a 
       biomarker of liver diseases -- Peripheral venous, portal 
       venous, hepatic venous, arterial and intrahepatic cytokine
       levels as biomarkers and functional correlations -- 
       Histological Biomarkers of Non-Alcoholic Fatty Liver 
       Disease -- Vascular cell adhesion molecule-1 (vcam-1) 
       expression in liver disease -- Bilirubin as a biomarker in
       liver disease -- Hydroxyproline as a biomarker in liver 
       disease -- Genetic biomarkers of paracetamol-induced acute
       liver failure -- PNPLA3 polymorphism and Nonalcoholic 
       Fatty Liver Disease -- Hepascore and it's application to 
       liver disease -- Model for End-Stage Liver Disease (MELD) 
       Score as a Biomarker -- Biomarkers in focus: Alanine 
       Aminotransferase -- PTX3 as a biomarker of liver disease 
520    There are numerous types of liver disease that may be due 
       to toxic agents (such as alcohol or drugs), infectious 
       agents including viruses, congenital conditions and even 
       poor dietary patterns. It has been suggested that there 
       are over 100 different types. As the consequences of liver
       failure can be devastating it is important that 
       appropriate diagnosis and monitoring is carried out. Much 
       of this characterisation entails the use of biological 
       indicators, i.e biomarkers. Biomarkers in Liver Disease 
       embraces a holistic approach by combining detailed 
       information on different conditions that affect the liver 
       and the use of biomarkers. Biomarkers are described in 
       terms of conventional, new and emerging analytes, 
       techniques, platforms and applications. It covers the 
       latest knowledge, trends and innovations. New platforms 
       are described which combine advances in biomedical 
       sciences, physics, computing and chemistry 
650  0 Liver|xDiseases|xMolecular diagnosis 
650  0 Biochemical markers 
650 14 Biomedicine 
650 24 Cancer Research 
650 24 Oncology 
650 24 Pharmacology/Toxicology 
700 1  Patel, Vinood B.,|eeditor 
700 1  Preedy, Victor R.,|eeditor 
710 2  SpringerLink (Online service) 
773 0  |tSpringer eBooks 
830  0 Biomarkers in disease: methods, discoveries and 
856 40 |u